[서울=뉴스핌] Reporter Yohan Bae = AP Technology, a company specializing in human milk oligosaccharide (HMO) manufacturing, announced on the 31st that it has obtained a patent for a composition for preventing and treating muscular atrophy and sarcopenia containing human milk oligosaccharide.
According to the rehabilitation medicine industry, regarding 10% of the population over 65 in Korea is diagnosed with sarcopenia. When the Asian diagnostic criteria are applied, 21.3% of men and 13.8% of women are patients with sarcopenia among the elderly over the age of 70. It is estimated that there are regarding 8.5 million people over the age of 65 in Korea, and 800,000 people with sarcopenia.
Muscular atrophy/sarcopenia is caused by the causes of aging such as ▲lack of mechanical stimulation, ▲astrocyte aging, ▲mitochondrial function decline, ▲stroke, ▲chronic disease, ▲excessive drug use, etc. When symptoms worsen, the range of fluctuations in blood sugar due to insulin resistance increases and it is difficult to control, which increases the incidence of various diseases such as diabetes, hyperlipidemia, weakened immunity, and joint disease.
The composition for prevention and treatment containing 2′-FL shows the effect of increasing the mitochondrial function that regulates the improvement of muscle mass and muscle strength, and increasing the expression of genes related to mitochondrial biosynthesis. This reduces the expression of components involved in muscle atrophy and sarcopenia, thereby enhancing muscle strength and preventing muscle atrophy and sarcopenia.
2′-FL is the most core component of human milk oligosaccharide (HMO), which is present only in breast milk, and performs functions such as the formation of a beneficial microbiome, virus excretion, immune activation, and brain cell growth. Recently, it has been attracting attention as a major factor affecting the immune system. With this patent, 2′-FL was found to be effective in sarcopenia, and the field of adaptation is expected to expand further in the future.
“Through this patent acquisition, we have confirmed the possibility that 2′-FL will be a new alternative for improving sarcopenia,” said an AP Technology official.
